The recent market-related and internal processes involving Becton Dickinson and BDX present an array of developments. Notably, Argus reduced its price target for the company from $230 to $180. Becton Dickinson's share price weakness and envisaged business separation have led to evaluations of its valuation. The company has completed a business combination of its Biosciences and Diagnostic Solutions with Waters Corporation.
Insider selling happened when Michael Feld offloaded some BDX shares. Davenport & Co LLC also sold some. These events led to assessments of whether Becton Dickinson's pricing signifies its DCF and P/E signals. The company announced a CFO transition plan and recorded a 4.5% drop since the last earnings report.
Becton Dickinson has announced a spin-off of its Biosciences and Diagnostic Solutions Business and a business merge with Waters. Amidst all this, the company has increased its dividend for the 54th consecutive year. There's a new immunology partnership with the University of Pennsylvania while its current valuation is being evaluated after a year-to-date share price decline. The company is also looking to redefine its capital allocation playbook with aggressive share buybacks.
Becton Dickinson (BDX) continues to evaluate valuation potentials following a recent share price rebound and launched new AI-enabled solutions to promote connectivity across healthcare settings.
Becton Dickinson and BDX News Analytics from Mon, 14 Jul 2025 07:00:00 GMT to Fri, 27 Mar 2026 20:15:13 GMT - Rating 0 - Innovation 6 - Information 8 - Rumor -8
